The MJ injection for weight loss: what actually happens when you start

You're holding the pen. Here's what happens next.

Picture the moment you take your first Mounjaro pen out of the fridge. A lot of people expect to feel it working immediately, that week's appetite collapsing overnight. That's not quite how it goes, and setting that expectation right from the start makes the early weeks much easier to get through.

The 2.5mg starting dose exists to let your body adjust, not to drive weight loss. Your prescriber will keep you at this level for around four weeks before considering a step up. During that time most people notice mild nausea, the occasional loose stool or a feeling of fullness after smaller amounts of food than usual. These are signs the medicine is active, the GIP and GLP-1 receptors in your gut and brain are responding to it, slowing how quickly your stomach empties and reducing appetite signals. The NHS tirzepatide medicines page has a plain-language breakdown of how the injection works and what to watch for.

Injection itself takes about fifteen seconds. You choose a site (abdomen, thigh, or upper arm) rotate it each week to avoid skin reactions, and press the pen against your skin until you hear or feel a click. There is no needle to cap or plunger to press. The pen handles the rest. A new needle should be used for each injection; keeping a stock of compatible needles makes this easy to keep up.

One thing worth mentioning: the pen must be kept refrigerated between 2°C and 8°C. Check the Patient Information Leaflet that comes with your pen for the exact rules on how long it can be left at room temperature if you're out for the day, because that window matters and it's specific to the product.

What the injections can realistically achieve, and what drives that

The trial results behind Mounjaro are the strongest for any weight-loss injection currently licensed in the UK. In SURMOUNT-1, published in the New England Journal of Medicine, adults with obesity who received the 15mg dose lost an average of around 20–21% of body weight over 72 weeks. That is a substantial figure by any standard, and it sits above the results seen with semaglutide 2.4mg in comparable trials. The SURMOUNT-5 head-to-head trial, also published in the NEJM in 2025, confirmed that tirzepatide produced greater average weight reduction than semaglutide 2.4mg directly.

What drives those results is the dual mechanism. Mounjaro activates both the GLP-1 receptor (shared with semaglutide) and the GIP receptor, which plays a separate role in how the body handles fat and blood sugar. That combination appears to produce a stronger appetite-suppressing effect than a single-receptor medicine alone.

Lifestyle factors still matter alongside the injection. People who make modest, sustainable changes to what they eat and how active they are tend to see better outcomes. Not because the injection doesn't work without that, but because the medicine creates a window of reduced hunger that is easier to act on when there's a loose plan in place. Your prescriber can talk through what realistic dietary changes look like for you, and if you want to understand more about how the m injection is used for weight loss, there's a dedicated page covering the specifics. If you're also weighing up how this compares to oral weight-loss medicines, there's a dedicated guide on that question.

Results do vary. Some people lose significantly more than the trial average; others less. The injection is not a guarantee, and prescribers who are straightforward about that are the ones worth trusting.

Who can use the MJ injection, and what the assessment covers

Because Mounjaro is a prescription-only medicine, the process starts with a clinical assessment, not a shopping basket. In the UK, the licensed eligibility criteria are a BMI of 30 or above, or a BMI of 27 and above alongside at least one weight-related health condition, for example, type 2 diabetes, high blood pressure, high cholesterol, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. You can check your BMI against these benchmarks using the NHS BMI calculator.

The assessment also covers your medical history, current medicines, and anything that might make tirzepatide less suitable. It is not a tick-box. A prescriber looks at your situation as a whole. For more detail on what determines eligibility, the weight thresholds for weight-loss injections page goes through it fully.

Mounjaro is not suitable during pregnancy, breastfeeding, or for anyone trying to conceive. It is not licensed for under-18s. If you take oral contraceptives, your prescriber will explain that adding a non-oral method of contraception is recommended during the first four weeks of treatment and for four weeks after each dose increase, because absorption of the pill may be affected.

On the NHS, access to Mounjaro is currently limited and follows a phased rollout based on BMI and the number of qualifying conditions. Private treatment through a regulated pharmacy does not require a referral and has no waiting list, provided you meet the clinical criteria. If you're still deciding which option suits you, reading about what a weight loss injection involves in practice can help clarify things before you look at costs. Understanding the cost landscape for weight-loss injections is a reasonable part of that decision.

Side effects to know about, and when to get help

The most common side effects of the Mounjaro injection are gastrointestinal. Nausea is the one people mention most. It tends to be at its worst in the days after a new pen or a dose step, then it softens. Constipation, diarrhoea, stomach discomfort, burping, and a general feeling of fullness are all reported, particularly in the early months. For most people these are an inconvenience, not a reason to stop.

Staying well hydrated matters more than it sounds. If nausea or vomiting is significant enough to reduce how much you're drinking, it can tip into dehydration quickly. Eating smaller amounts, avoiding fatty or very rich food in the early weeks, and spacing meals out can all help manage the GI effects.

There are symptoms that need prompt medical attention. Severe stomach pain that spreads to the back, with or without vomiting, should be assessed urgently, acute pancreatitis is a known but uncommon risk with this class of medicine, and the MHRA has flagged it as something prescribers and patients should be aware of. Signs of an allergic reaction, gallbladder symptoms, or any sudden changes in mood also warrant a call to a clinical team. You can report any unexpected side effects through the MHRA Yellow Card scheme.

If you want to read more about the broader category this injection belongs to, how weight-loss injections work as a group is a good starting point. And if you'd like a prescriber at nume to review whether Mounjaro is the right fit for your situation, start your free consultation, a real clinician reads every response, the same working day.